Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)

Authors

Institutions

Publication Details

Journal
Modern Rheumatology
Published
2026-03-03
DOI
https://doi.org/10.1093/mr/roag020
Primary Topic
IgG4-Related and Inflammatory Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)

Hisanori Umehara, Hirokazu Sato, Yoshiya Tanaka, Kosuke Uchima et al.
Modern Rheumatology
IgG4-Related and Inflammatory Diseases
article

Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)

Hisanori Umehara, Hirokazu Sato, Yoshiya Tanaka, Kosuke Uchima, Kawai Kouji, Kazuichi Okazaki
article en

Abstract

No abstract available for this paper.
Modern Rheumatology
Kansai Medical University (JP), University of Occupational and Environmental Health Japan (JP), Nagahama City Hospital (JP), Tanabe Research Laboratories (US)
Good health and well-being
Openalex Percentile: Top 30%
IgG4-Related and Inflammatory Diseases
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.